Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Caroline Fenton, Caroline M Perry

Abstract

Gemtuzumab ozogamicin (Mylotarg) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalization, releases a derivative of the cytotoxic calicheamicin component. In the US, it is approved as monotherapy in patients aged>or=60 years with a first relapse of AML who are ineligible for other cytotoxic therapy. Monotherapy with gemtuzumab ozogamicin results in complete remission (CR) or CR with incomplete platelet recovery (CRp) in approximate, equals 25% of adults (including those aged>or=60 years) with CD33-positive AML in first relapse. Preliminary data indicate a potential role for gemtuzumab ozogamicin as a component of induction or consolidation regimens in adults and, based on an early study, in the treatment of children with AML, although randomized, controlled studies are needed. Serious adverse events, notably hepatotoxicity, characterize its tolerability profile, but gemtuzumab ozogamicin is comparatively well tolerated by most patients. Gemtuzumab ozogamicin is a valuable new treatment option for patients aged>or=60 years with CD33-positive AML in first relapse for whom other cytotoxic chemotherapy is not con...Continue Reading

Citations

Aug 29, 2007·Clinics in Liver Disease·Edmundo A Rodriguez-Frias, William M Lee
Sep 5, 2008·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Ramses G ForsythPancras C W Hogendoorn
Jun 11, 2009·Biomedit︠s︡inskai︠a︡ khimii︠a︡·V P BaklaushevV P Chekhonin
Sep 3, 2020·Journal of Clinical Pharmacology·Joseph E MaakaronAlice S Mims

❮ Previous
Next ❯

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.